Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseNick Dekker, Johannes M. F. G. Aerts, J.E.M. Groener et al.|Blood|2011Cited by 288
Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1Pramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|JAMA|2015Cited by 156
Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trialPramod K. Mistry, Michel Peterschmitt, Elena Lukina et al.|American Journal of Hematology|2017Cited by 99
Genome‐wide association study of N370S homozygous Gaucher disease reveals the candidacy of <i>CLN8</i> gene as a genetic modifier contributing to extreme phenotypic variationHu Zhang, Pramod K. Mistry, Philip Stein et al.|American Journal of Hematology|2012Cited by 59